U.S. Life Sciences Company GeisterBio Expands Operations in Winston-Salem
Company receives grants from the NSF Regenerative Medicine Engine in North Carolina and Greater Winston-Salem Inc. BioNest Fund.
WINSTON-SALEM, N.C., Sept. 30, 2026 – GeisterBio, Inc., a U.S. life sciences company founded by Austrian entrepreneur Noah Geister, is expanding its operations in Winston-Salem.
Geister founded the company in the United States after visiting the region in March 2025 and experiencing its regenerative medicine research and commercialization ecosystem. Working with an international team, GeisterBio is now building out its local laboratory and quality-control activities with support from a Seed Project Award from the NSF Regenerative Medicine Engine in North Carolina and Greater Winston-Salem Inc.’s BioNest Fund.
GeisterBio’s near-term commercialization initiative, SingleScan, is designed to improve the consistency and quantitative comparability of CT measurements, helping researchers and clinicians generate more reliable imaging data. It is also developing a full-stack biomanufacturing system that produces perfused tissues, with the goal of achieving patient-matched organs like the heart and liver for transplantation.
The company plans to establish a lab and quality control operation at One Technology Place in the Innovation Quarter and make its first two local hires within the first six months. It projects 8-12 jobs over the next three years.
“A location in the Innovation Quarter is strategically important because it places our work near the Wake Forest Institute for Regenerative Medicine, the Regenerative Medicine Engine in North Carolina, the Wake Forest University School of Medicine, and other key partners, while providing access to the regional life-sciences talent and supplier network,” says GeisterBio founder and Chief Executive Officer Noah Geister.
GeisterBio recently received a $250,000 Seed Project Award from the Regenerative Medicine Engine in North Carolina, which supports the development and commercialization of regenerative medicine technologies. The NSF-funded Regenerative Medicine Engine is led by the Wake Forest Institute for Regenerative Medicine (WFIRM) and connects companies with specialized infrastructure, technical expertise, workforce resources, and commercialization support across the region.
The BioNest Fund supports life sciences companies expanding or locating in Winston-Salem and is made possible through the Whitaker Park Development Authority. It fills the gap left when projects in the life sciences sector often don’t qualify for traditional public incentives.
This project is a great example of the BioNest Fund working hand-in-hand with other resources in the local ecosystem like the Regenerative Medicine Engine to convert an international prospect into a Winston-Salem operation,” says Ellis Keifer, Vice President of Economic Development for Greater Winston-Salem Inc.
“GeisterBio’s decision to establish its U.S. operating base in Winston-Salem reflects the growing strength of our life sciences ecosystem and its global reach,” says Isaac Perry, Head of Biotech and Life Science Ecosystem Development for the Innovation Quarter and Greater Winston-Salem Inc. “Companies developing breakthrough technologies are increasingly recognizing the value of locating here, where they can access world-class research institutions, specialized talent, entrepreneurial support, and a collaborative network that helps accelerate innovation and commercialization.”
###
About GeisterBio
GeisterBio, Inc. is a U.S. biotechnology company developing a full-stack biomanufacturing platform engineered for printing human hearts for transplantation. The company brings together multi-material bioprinting, biomaterials, perfusion, tissue maturation, software and quality control. It has built its first-generation bioprinter and supporting platform prototypes, with an external system deployed at North Carolina A&T State University. Human tissue models for biomedicalresearch and drug testing form a distinct application of the platform. GeisterBio also develops SingleScan, a reference-phantom and software approach to quantitative CT measurement comparability. Founded by Austrian entrepreneur Noah Geister, the company combines U.S. operations with an international team and R&D in Austria. Learn more at geisterbio.com.
About the Wake Forest Institute for Regenerative Medicine
The Wake Forest Institute for Regenerative Medicine (WFIRM) is recognized as an international leader from scientific discovery to their translation into clinical therapies, with many world firsts, including the development of the first permanently implanted engineered organ in a human, the discovery of a novel highly multipotent source of stem cells derived from amniotic fluid and placenta that are being used clinically, the advancement of 3D printing strategies for manufacturing tissues and organs, and the use of regenerative medicine strategies to create organoid and body on a chip technologies currently being applied for patient related indications. Over 500 people at the institute, the largest in the world, work on more than 50 different tissues and organs. Several basic principles of tissue engineering and regenerative medicine were first developed at the institute.
WFIRM researchers have successfully engineered replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 18 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney and vaginal organs, have been successfully used in human patients. The institute, which is part of Wake Forest University School of Medicine, the academic core of Advocate Health, is in Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients. The institute is making a global difference in regenerative medicine through collaborations with over 600 entities and institutions worldwide, through its government, academic and industry partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing.
Learn more at wfirm.org.
About Greater Winston-Salem Inc.
Greater Winston-Salem Inc., the 2024 ACCE National Chamber of the Year, supports Winston-Salem/Forsyth County’s economic growth through economic recruitment and retention, talent and wi Geister Bio – BioNest.docx
worktorce development, advocacy, and entrepreneurial programming. We are committed to bringing an innovative mindset and collaborative efforts to initiatives that develop a vibrant community that’s good for business growth and sustainability. Our efforts are informed by our 2030 Vision: to be a top mid-sized city for economic growth, to be a more equitable community, and to be the best place to raise a family. Learn more at winstonsalem.com.
About the Innovation Quarter
The Innovation Quarter is a vibrant, mixed-use innovation district in downtown Winston-Salem, North Carolina, and a powerful example of place-based transformation. Anchored by Wake Forest University School of Medicine, the district has evolved over more than two decades from a historic manufacturing center into a globally recognized hub for medical education, digital health, biomedical science and regenerative medicine research. Today, the Innovation Quarter is home to a dynamic ecosystem of nearly 2,000 students, more than 4,500 workers and 115 companies —ranging from startups and sole proprietors to emerging and established enterprises —who together form a vital entrepreneurial community. By blending state-of-the-art research and academic facilities with ,residential, commercial and community amenities, the Innovation Quarter fuels innovation, drives economic development and contributes meaningfully to the nation’s innovation culture.